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Resovist Enhanced MR Imaging of the Liver:
Does Quantitative Assessment Help in Focal
Lesion Classification and Characterization?
Lucia Santoro, MD,1 Luigi Grazioli, MD,2 Antonella Filippone, MD,3
Emanuele Grassedonio, MD,4 Giacomo Belli, MS,5 and Stefano Colagrande, MD1*
Purpose: To improve characterization of focal liver lesions
by a prospective quantitative analysis of percentage signal
intensity change, in dynamic and late phases after slow
(0.5 mL/s) Resovist administration.
Materials and Methods: Seventy-three patients were sub-
mitted on clinical indication to MR examination with
Resovist. Signal intensity of 92 detected focal lesions
(5–80 mm) were measured with regions of interest and
normalized to paravertebral muscle in arterial, portal,
equilibrium and T1/T2 late phases, by two observers in
conference. Five values of percentage variations per
patient were obtained and statistically evaluated.
Results: The enhancement obtained on dynamic study is
more suitable in hemangiomas and focal nodular hyper-
plasias than in adenomas and hepatocellular carcinomas.
To discriminate benign versus malignant lesions on late-
phase-T2-weighted images, a cutoff ¼ 26%, allowed
sensitivity and specificity values of 97.4% and 97.7%,
respectively. Area under the receiver operating character-
istic (ROC) curve was 0.99. To differentiate hemangioma
versus all other focal liver lesions, on late-phase-T1-
weighted images, a cutoff ¼ þ40% permitted sensitivity
and specificity values of 90.5% and 98.0%, respectively.
Area under the ROC curve was 0.98.
Conclusion: Late phase quantitative evaluation after slow
Resovist administration, allows to differentiate malignant
from benign hepatic masses and hemangiomas from all
the others focal liver lesions, on T2-/T1-weighted acquisi-
tions, respectively.
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RESOVIST (SHU 555 A, Bayer Schering Pharma, Ber-
lin, Germany) is a T2 superparamagnetic iron oxide
(SPIO) contrast agent (CA). After intravenous adminis-
tration, it is actively uptaken by cells of the reticulo-
endothelial system (RES) of the liver and spleen (1–3).
As a consequence, Resovist was primarily used to
improve focal liver lesion detection rate (4–7). Normal
liver/splenic parenchyma and benign masses have a
well represented RES and after SPIO administration
signal intensity (SI) loss is detectable. Conversely, due
to relative or absolute lack of RES, malignant lesions
have no phagocytic capabilities, and do not change
their SI in T2-weighted images, thus increasing con-
spicuity versus surrounding normal liver parenchyma.
Because the lesions T2 signal changes in proportion
to Kupffer cell activity (8), some authors used SPIO to
characterize focal liver lesions. Most have attempted a
qualitative study (8–11), while only a few authors
have adopted a quantitative analysis to improve char-
acterization of metastases (12), hemangiomas (13),
and focal liver lesions in general (14,15). The latter
evaluation has been made only in the delayed RES
specific phase without any information about dynamic
T1 study.
SPIO also shows a T1 effect which is more relevant
in a well hydrated environment, thus Resovist has
also been used for T1-weighted imaging with vascular
opacification and peculiar T1 enhancement of heman-
giomas (14). Some authors (16,17) have reported dis-
satisfaction with SPIO arterial phase after bolus injec-
tion in clinical practice. A new protocol has been
proposed to improve the enhancement in dynamic
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phase (at the rate of 0.5 mL/s against the usual rate
of 2 mL/s) (18).
The aim of this prospective study was to improve
the classification (i.e., attribution to a benign or malig-
nant class) and characterization of the most frequent
focal liver lesions, by a simple quantitative analysis of
percentage signal intensity changes achievable during
routine acquisitions, in dynamic and delayed phases,
after slow Resovist administration.
MATERIALS AND METHODS
Study Population
From March 2007 to November 2008, 80 patients
were enrolled for MRI with Resovist. The inclusion cri-
teria were as follows: of-age patients, routinely
referred for MR to follow up known benign focal liver
lesion(s) or to confirm malignant mass(es) already
detected with previous CT; no more than three
lesions; no moderate to severe steatosis diagnosed by
visual grading criterion (19). Of the 80 patients en-
rolled, 2 refused MR examination (claustrophobia)
and 1 declined administration of CA. Resovist-
enhanced MR imaging could not be completed in two
patients because of slight adverse reactions immedi-
ately after infusion of the CA; two patients were
excluded for technical reasons (respiratory artifacts).
The final study group included 73 patients (29 males
and 44 females; mean age, 54  15 years; range, 24–
82 years) with a total amount of 92 lesions, ranging in
diameter from 5 to 80 mm (mean, 28.48  17.44).
Patient diagnosis was provided by combined clinical,
imaging, laboratory and pathological findings (Table
1). Four patients presented with 3 lesions, 12 with 2
lesions (among these, 2 patients had two different
types of lesions: 1 hemangioma and 1 metastasis; 1
focal nodular hyperplasia [FNH] and 1 adenoma),
while remaining 56 showed only one nodule. Liver
metastases arose from the following primary tumors:
breast cancer (10 patients), colorectal (10 patients),
lung (3 patients), pancreatic (2 patients), gastric (2
patients), larynx, carcinoid tumor, gastrointestinal
stromal tumor, unknown origin (1 patient).
To obtain data about normal liver parenchyma, we
evaluated 28 subjects (7 males and 21 females; mean
age, 50  15 years; range, 26–80 years) undergoing
MR examination with Resovist to study splenic pa-
thology (focal lesions in normal sized spleen); these
patients had no clinical and/or imaging signs of liver
pathology. All examinations were carried out for clini-
cal indications and patients, after being informed
about possible risks of intense magnetic field expo-
sure and contrast medium injection, gave their writ-
ten consent. Ethical committee approval and patient
permission were not required for this prospective
study, as patient privacy was maintained and patient
care was not affected. All the lesions had already been
detected and the purpose of the MR examination was
to evaluate possible change in dimensions, number of
benign masses or to confirm the presence of malig-
nancy. All data and information derived from and per-
taining to the study were under the exclusive control
of the investigating radiologists.
MR Imaging Protocol
All MR examinations were performed using a 1.5
Tesla (T) imaging system (Symphony, TIM Class, Sie-
mens, Erlangen, Germany) equipped with a four-
channel phased array multicoil, adequately positioned
to cover the upper abdomen of the patient lying in a
supine position. The scanner provides a maximum
gradient strength of 30 mT/m, with a peak slew rate
of 120 mT/m/ms. The baseline MRI protocol included
the following transverse acquisitions:
(1) T2-weighted half-Fourier single-shot turbo spin-
echo (HASTE) free-breath sequence: repetition time/
echo time (TR/TE) ¼ 8/79 ms, echo-train length ¼
90, slice thickness ¼ 5 mm, intersection gap ¼ 10%,
field of view (FOV) ¼ 350–400 mm, effective matrix
size ¼ 256  165, number signal averages (NSA) ¼ 1,
acquisition time ¼ 2–3 min;
(2) T1-weighted 3D-GRE with volumetric interpo-
lated breath-hold examination (VIBE) fat sat
sequence: TR/TE ¼ 3.8/1.5 ms, slice thickness ¼ 4
mm, intersection gap ¼ 10%, flip angle ¼ 80, FOV ¼
350–400 mm, effective matrix size ¼ 256  169, par-
allel imaging reduction factor ¼ 2, NSA ¼ 1, acquisi-
tion time ¼ 16 s. This sequence includes a sequential
phase-encode order in the ky direction and a centric
phase-encode reordering in the kz direction (partitions
loop) to optimize fat-saturation uniformity.
After CA administration, the 3D sequence was
repeated during hepatic artery phase (HAP) with a
delay determined by Care Bolus technique. The acqui-
sition was repeated again at 75 s during portal vein
phase (PVP), at 180 s during equilibrium phase (EP)
and at 10 min in late phase (LP). The HASTE
sequence was repeated during the LP.
The Care Bolus technique in the sagittal and para-
sagittal orientations was used to determine the exact
time to begin the artery phase acquisition, considering
one scan per second: TR/TE ¼ 3.5/1.1 ms, slice
thickness ¼ 60 mm, intersection gap ¼ 20%, FOV ¼
400 mm, effective matrix size ¼ 128  128, NSA ¼ 2.
The region of interest (ROI) with appropriate size was
located in the abdominal aorta at the level of the ce-
liac trunk. The Care Bolus reached the ROI level after
20–30 s, on the average; we began the GRE-3D VIBE
sequence acquisition with a further delay of 10 s, and
then after 30–40 s from the beginning of the CA
Table 1
Case Distribution and Diagnosis
92 Lesions (73 patients) Diagnosis (patients)
21 Hemangiomas (16) At least 1 year MR follow-up (16)
10 Adenomas (4) Gadolinium BOPTA MR and
biopsy (4)
18 FNHs (15) Gadolinium BOPTA MR (15)
8 HCCs (7) Barcelona 2005 criteria (4)
and biopsy (3)
35 Metastases (31) Clinical/imaging follow-up (16)
and biopsy (15)
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administration, by an automatic breath-hold (expira-
tory) recorded voice command (given 6 s in advance to
the start of the acquisition).
Resovist was administered in a bolus by prefilled
syringe (dose 0.9 mL in patients with a body weight
lower than 60 kg, and 1.4 mL higher than 60 kg) in
the distal part of a connecting line into an antecubital
vein, followed by flushing with 20 mL of saline solu-
tion using an automated injector (Spectris Solaris EP,
MedRad, Indianola, PA), at the rate of 0.5 mL/s to
obtain a wider window of enhancement (18). The du-
ration of the entire administration (CA plus 20 mL sa-
line flush) was approximately 40–42 s. To avoid too
great a difference in the administered CA quantity
among various sized patients, we adopted an empiri-
cal rule, limiting the dose to 1.2 mL until the weight
of 75 kg. So the range was from 0.015 to 0.018 mL of
CA per kg of body weight for patients ranging from 50
to 90 kg, that is 0.9 mL < 60 kg, 1.2 mL from 60 to
75 kg, 1.4 mL > 75 kg. Patients were monitored for 2
h after the examination for adverse effects.
Image Analysis
SIs of normal liver parenchyma and hepatic lesions
were measured and normalized to paravertebral mus-
cle for each patient before and after injection of CA in
HAP, PVP, EP, LP, T1- and T2-weighted. Each SI read-
ing was obtained in conference by two observers with
ROIs placed as described below, and disagreements
were resolved by consensus. Because of minimum
changes in the position of the patients during exami-
nations, pre and post SHU-555A ROIs were manually
defined on each image as much reproducibly as possi-
ble. A ROI of 400 mm2 was used to measure the SI of
the healthy liver parenchyma; ROIs were placed to
avoid large blood vessels, boards and artifacts, so that
standard deviations (SDs) were no higher than 10%.
According to nodular size, the largest ROIs were used
to measure the SI of focal lesions; ROIs were placed to
avoid necrosis and scarring within the nodular
masses, so that SDs were always no higher than 20%.
SIs were measured in each sequence and to avoid
rescaling phenomenon, were normalized to paraverte-
bral muscle SIs.
Percentage signal intensity change (PSIC) was cal-
culated as: [(SI post-CA – SI pre-CA/ SI pre-CA) 100]
and was normalized (NPSIC) to paravertebral muscle
SI using the following formula: NPSIC (in percent) ¼
[(SI post-CA / SI pre-CA)  (N pre-CA / N post-CA) –1]
100.
We obtained 5 NPSIC evaluations (five values of per-
centage variations) per patient: T1-weighted HAP,
PVP, EP, LP, T2-weighted LP. Every quantitative evalu-
ation was decided in conference by the two main
investigators, both with more than 15 years of experi-
ence in liver MR imaging and 5 years in imaging with
SPIO; conflicts were resolved by consensus.
Statistical analysis
Statistical evaluations were performed using the SPSS
package version 12 (SPSS Inc., Chicago, IL). Data are
expressed and were analyzed as groups of lesions and
as individual lesions.
Group Analysis
We reported mean  standard deviation in all phases;
SIs in the liver and hepatic lesions before and after
SHU-555A were evaluated to find any significant dif-
ference. Normalized SIs for normal liver parenchyma
and all lesions, within each group (normal liver, FNH,
hemangioma, hepatocellular carcinoma [HCC], metas-
tasis, adenoma), were tested using the Student paired
t-test for significance at a level P < 0.01. Statistical
analysis of NPSICs mean values for all groups (liver
and focal lesions) was performed by analysis of var-
iance test. It followed a post hoc comparison (Tam-
hane test) to find out which groups were significantly
different from each other and which were not.
Individual Analysis
We used scatter plot representation. Using our best
results (to classify/characterize focal liver lesions) we
constructed a receiver operating characteristic (ROC)
curve to determine the point nearest to the upper left
corner, corresponding to the best sensitivity and spec-
ificity couple of the test; the area under the curve was
also calculated. Logistic regression preanalysis was
made.
RESULTS
Two patients experienced slight adverse reactions
(itch and flushing with facial and neck erythema, con-
junctivitis) which disappeared without any therapy in
approximately 5 min; however, the examinations were
completed without early contrastographic phases and
these patients were not included in the study group.
Group Results
Mean SI  SD and statistically significant SI differ-
ences are shown (Table 2). NPSIC values of each class
(normal liver, adenoma, hemangioma, FNH, HCC, and
metastasis) in all phases are detailed (Table 3)
(Fig. 1). On T2-weighted images, Student paired t-test
was statistically significant for liver, FNH, adenoma
and hemangiomas before and after CA administration,
at the sole late acquisitions (Fig. 2). Conversely, no
statistically significant SI changes for metastases and
HCCs were observed at the same comparison. T1-
weighted images had statistically significant SI change
only for hemangiomas in dynamic and late phases, for
FNH in dynamic phases, and for liver in arterial and
portal phases (Table 2) (Fig. 3). On T2-weighted LP
sequence, NPSIC mean values were significantly dif-
ferent (Tamhane test) in normal liver and benign
lesions versus malignant masses; no significant differ-
ence was found between normal liver and benign
lesions. On T1-weighted HAP sequence, FNHs were
significantly different from metastases. On T1-
weighted PVP hemangiomas were significantly differ-
ent from all others except FNHs; on T1-weighted EP
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and LP sequence, hemangiomas were significantly dif-
ferent from all others (Table 3). The most relevant
results for classifying focal liver lesions were observed
at T2 and T1-weighted LP acquisitions (Table 2). T2
NPSIC ranged from 22 to 73, mean 43  13 for
benign lesions, and from 22 to þ58 mean þ1  18,
for malignant lesions; the difference between benign/
malignant groups was statistically significant (P <
0.01). T1-weighted NPSIC were always higher than
þ19 for hemangiomas and always lower than þ60 for
other lesions; the difference between the hemangi-
oma/nonhemangioma groups was statistically signifi-
cant (P < 0.01) (Figs. 2–5).
Individual Results
On the basis of group results, we report in a scatter
plot (as individual values) only T2 and T1-weighted LP
NPSIC values for each lesion, to show different distri-
bution for benign versus malignant lesions (Fig. 6)
and for hemangioma versus nonhemangioma (Fig. 7).
Logistic regression performed on these values con-
firmed the hypothesis of significant dependence
between NPSIC and malignant status, on T2-weighted
LP images (P ¼ 0.004); between NPSIC and hemangi-
omas status, on T1-weighted LP images (P ¼ 0.0001).
ROC analysis gave us evidence for several sensitivity
and specificity values versus NPSIC.
To distinguish between benign versus malignant
lesions on T2-weighted images, a cutoff ¼ 26%
allowed 97.4% sensitivity and 97.7% specificity. Area
under the ROC curve was 0.99. Two false positives,
represented by one FNH and one adenoma, and one
false negative due to well differentiated HCC, were
found (Fig. 6).
To distinguish hemangioma from all other focal liver
lesions on T1-weighted images, a cutoff ¼ þ40% per-
mitted 90.5% sensitivity and 98.0% specificity. Area
under the ROC curve was 0.98. Two false positives,
represented by one FNH (not the same as reported
above) and one metastasis, and two false negatives
due to hemangiomas (6- and 8-mm diameter) were
detected (Fig. 7).
DISCUSSION
Quantitative evaluation of enhancement induced by
slow SHU-555A administration allowed us to differen-
tiate benign (hemangiomas, adenomas, and FNHs)
from malignant (HCCs and metastases) lesions on T2-
weighted late phase images in our patients with a cut-
off ¼ 26%, 97.4% sensitivity and 97.7% specificity
(Fig. 6). On T1-weighted late phase images, a cutoff ¼
þ40% differentiated hemangiomas from all other focal
liver lesions with 90.5% sensitivity and 98.0% speci-
ficity (Fig. 7).
In the analysis of groups of lesions, hemangiomas
were significantly different from all other lesions also
on T1-weighted EP sequence. Finally, dynamic study
with slow bolus demonstrated statistically significant
SI change versus unenhanced scan for liver, FNH, he-
mangioma (in HAP and PVP), and hemangiomas and
FNHs (in EP) (Fig. 1; Tables 2 and 3). Resovist with
slow bolus provided a suitable dynamic study of
hemangiomas (Fig. 3) and FNHs. On the contrary,
adenomas and HCCs (Fig. 5) were not significantly
enhanced at dynamic study. In only three cases (2
adenomas and 1 HCC, and then 3 lesions out of 18)
was valid enhancement on HAP detected (Fig. 2). This
last finding is in contrast with a prior study with slow
bolus Resovist administration, where the best
enhancement achievable did not seem related to a
particular category of focal lesion and was appreciable
in all histological types with the same evidence (18).
Table 2
Normalized Signal Intensity Mean Value*
Unenhanced phase Enhanced phases
Signal intensity T2-weighted T1-weighted Arterial Portal venous Equilibrium Delayed phase T1 Delayed phase T2
Liver 1.19  0.5 1.27  0.4 1.38  0.44* 1.43  0.45* 1.35  0.44 1.18  0.44 0.5  0.22*
Hemangiomas 2.7  1.75 0.85  0.37 1.18  0.66* 1.38  0.71* 1.45  0.67* 1.47  0.61* 1.39  1.09*
Adenomas 1.48  0.44 1.39  0.53 1.42  0.36 1.39  0.43 1.54  0.69 1.35  0.45 0.83  0.26*
FNHs 1.69  0.66 1.01  0.34 1.23  0.43* 1.18  0.41* 1.09  0.38* 1  0.35 0.93  0.51*
HCCs 1.16  0.57 0.57  0.20 0.66  0.21 0.65  0.23 0.61  0.23 0.61  0.19 1.17  0.52
Metastases 1.48  1.04 0.76  0.49 0.74  0.42 0.75  0.42 0.74  0.47 0.79  0.49 1.46  1.01
*Data are means  standard deviation. When asterisk (*) is present, the difference of signal intensity between pre-SPIO and post-SPIO
administration was statistically significant (P < 0.01).
Table 3
Normalized Percentage Signal Intensity Change (NPSIC)*
NPSIC % Arterial Portal venous Equilibrium Delayed phase T1 Delayed phase T2
Liver 9  10 13  11 7  12 6  15 56  10
Hemangiomas 36  47 63  52 74  43 78  34 50  13
Adenomas 8  20 5  21 9  15 1  7 43  10
FNHs 23  16 17  13 8  15 2  20 44  14
HCCs 5  10 9  12 6  10 12  14 1  21
Metastases 2  22 2  20 3  13 6  17 2  18
*Data are means  standard deviation.
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However, the previous experience was performed with
a qualitative approach, and we believe that lesion
changes are more appreciable by quantitative evalua-
tion, which is easy and rapid to obtain by the pro-
posed method, rather than by visual qualitative evalu-
ation which often misjudges the enhancement, in
particular on the T2-weighted acquisition, in our
opinion because of the strong rescaling phenomenon
induced by Resovist administration (Figs. 2, 4, 5). In
our series, the rescaling bias was avoided by intro-
duction of the normalization factor (a muscular struc-
ture of the back). One possible explanation for the dif-
ferent contrastographic features identified may be due
to the typical enhancement of hemangiomas and
FNHs during dynamic acquisition, usually less tran-
sient than the enhancement shown in adenomas and
HCCs. Generally, we can confirm the minor conspicu-
ity upon dynamic evaluation of hypervascular lesions
after Resovist administration versus gadolinium che-
lates CA, despite the adoption of the slow infusion
protocol, noted in a prior study (18).
In our analysis, with the given cutoff, we found in
T2-weighted LP values, two false positives (one FNH,
one adenoma) and one false negative (one HCC) (Fig.
6). The FNH had a large T2-hyperintense scar, which
we presume contained a lower quantity of RES and
then minor CA phagocytosis, thus explaining the
Figure 2. a–f: Hepatic adenoma. On the unenhanced T1-weighted VIBE acquisition (a) a nodule heterogeneously hypointense
versus surrounding right liver lobe parenchyma, is detectable. After slow bolus Resovist administration nodule enhances in
the arterial phase (b), without any appreciable wash-out during portal venous (c) and equilibrium phases (d). On the unen-
hanced HASTE T2-weighted sequence (e), the lesion appears hyperintense versus liver parenchyma, without any significant
changes on the 10-min contrast-enhanced acquisition (f), at visual assessment. However, the quantitative analysis demon-
strated a 33% signal loss of the nodule which appears still hyperintense due to a 53% signal loss of the surrounding
parenchyma. Note, in all the images (a–f), some little cysts in the anterior portion of the liver parenchyma.
Figure 1. Graph-Normalized Percentage Signal Intensity
Change (NPSIC). Enhancement values of each class (normal
liver, adenoma, hemangioma, FNH, HCC, and metastasis)
are graphically represented in all acquisition phases.
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slight SI loss. We hypothesize the same reason for the
adenoma, which is well known to have a variable
amount of RES. On the contrary, the HCC was a well
differentiated type, which usually maintains a normal
amount of RES.
In T1-weighted LP values analysis, two false posi-
tives (one FNH, one metastasis) and two false negatives
(two hemangiomas) were found (Fig. 7). FNH showed a
hyperintense scar at 90-min acquisition after liver spe-
cific gadolinium chelates administration and so we
believed this scar was rich in soft interstitial tissue.
Metastasis was hypervascular (from carcinoid tumor).
In both cases, we suppose there was a trapping phe-
nomenon similar to that which explains late hyperin-
tensity of hemangiomas: we mean that the particles of
CA enter the pathological vessels of the hypervascular
nodule and the lacunae of the hemangiomas, they
cluster and remain into vascular spaces, lacking the
effect of the RES. Either the first or the second nodule
was appropriately classified as benign and malignant,
respectively, on the basis of their T2 patterns. In the
case of metastasis it is probable that trapping was suf-
ficient to determine the T1 enhancement but not to
induce a significant T2 signal loss. Both hemangiomas
presented a great signal loss in T2-weighted acquisi-
tion. This has led us to believe that a significant trap-
ping effect with SPIO particles cluster occurred in
these hemangiomas, determining an important signal
decrease both in T2 and T1-weighted sequences. More-
over these hemangiomas had very small dimension, so
we believe the minor SI measured, was also due to a
partial volume effect. On the whole, the total amount
of errors in characterization was only due to T2 false
positives in 3 out of 92 lesions (3.26%).
There are other quantitative studies regarding the
use of the SPIO CA to improve characterization of me-
tastases (12), hemangiomas (13), and various focal
liver lesions (14,15) in the literature. Only the latter
proposed a quantitative characterization in a large se-
ries of different focal liver lesions; however, unlike our
study, these authors carried out the quantitative
study only in the late T2-weighted phase and without
signal normalization. Other authors (13,14) normal-
ized SI to the muscle, but the adoption of Endorem
(ferumoxide, Guerbet, Aulnay-sous-Bois, France) did
not allow them to perform the dynamic study. Accord-
ing to our results, these authors found no significant
SI change in T2-weighted acquisitions for metastases
(12) and HCCs (13,15), and confirmed significant SI
loss for FNHs (13–15), hemangiomas (13–15), and
adenomas (14,15). T1-weighted late phase study
results are similar for hemangiomas as well (13,14).
Chen et al compared Endorem and Resovist by a
quantitative analysis of liver/spleen parenchyma and
liver metastases with results analogous to ours for
liver parenchyma and metastases, both in T2 and T1-
weighted sequences. However, the studies are quite
dissimilar because they administered Resovist in a
rapid bolus and studied secondary tumors only, while
we did not evaluate the spleen.
Figure 3. a–d: Hepatic hemangi-
oma. On the unenhanced T1-
weighted VIBE acquisition (a), a
large nodule hypointense versus
surrounding right liver lobe paren-
chyma, is appreciable. After slow
bolus Resovist administration, nod-
ule shows a slow fill-in phenomenon
in the arterial and equilibrium
phases (b,c), becoming almost isoin-
tense versus surrounding paren-
chyma on the 10-min T1-weighted
acquisition (d).
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So we can affirm that our work could be of some in-
terest and novelty because we used (i) a quantitative
rather than qualitative approach, (ii) a slow bolus
administration, (iii) normalization with paravertebral
muscle, and (iv) a large series of different focal liver
lesions. Nevertheless, our study has two main limita-
tions, as well.
First, the number of studied lesions is small, due to
the interruption of the trial because in our country
distribution of Resovist was stopped at the end of
2008. However, each class of the more frequent
masses is represented and our results can at least
provide an indication of the performance achieved by
the described quantitative method.
Second, we did not perform the evaluation with the
T2*-weighted gradient-echo sequences. Whether the
latter sequence or T2-weighted fast spin-echo images
are superior in the liver-specific phase of SPIO-
enhanced liver MRI is still controversial (20–24). An
experience similar to the ours concluded that T2*-
weighted sequences are mainly helpful for lesion
detection but other authors present discordant con-
clusions (21,24). Our aim was not lesion detection but
lesion characterization. Our routine liver protocol
does not comprise T2*-weighted sequence due to its
low soft-tissue contrast, despite the great sensitivity
to magnetic susceptibility. We chose HASTE se-
quences because they are free-breath, rapid, with
high spatial resolution, well reproducible and largely
used in clinical practice. Finally, in a preliminary an-
ecdotal study we compared a T2*-weighted sequence
with HASTE by the quantitative method. The resultant
values, expressed as a percentage (NPSIC,% of SI vari-
ation), did not show any significant difference between
HASTE and T2*-weighted acquisitions. The difference
compared with this previous report (15) is in the lack
of normalizing factor in that study.
In our opinion, the greater problem of Resovist in
favor of a constant adoption in the daily practice was
the inconstant performance in dynamic phases, in
particular in arterial acquisition, mainly due to the
small quantity of administered CA (maximum 1.4 mL)
and then to the little duration time of the arterial con-
trastographic window, even in the presence of the 20-
mL saline flush. Nevertheless, the inconstant contras-
tographic effect in the arterial phase was ineffective in
the total amount of errors in characterization,
because the real add-on value of Resovist is at 10-min
T2-weighted acquisition, being almost always a com-
plimentary examination, performed after iodinated CT
Figure 4. a–f: Liver metastasis (from colon cancer). On the unenhanced T1-weighted VIBE acquisition, in the medial part of
the VII segment, a nodule hypointense versus surrounding parenchyma, is visible (a). After slow bolus Resovist administra-
tion, no enhancement can be detected on the arterial and portal phases (b,c), while on the 10-min T1 image (d) a peripheral
ring of enhancement due to the compressed adjacent liver parenchyma, is demonstrable. On the unenhanced HASTE T2-
weighted sequence (e), the lesion appears hyperintense versus liver parenchyma, with central necrotic scar. No signal inten-
sity change, also at quantitative analysis, is demonstrable on the 10-min contrast-enhanced acquisition (f), where the nodule
appears more hyperintense due to the signal decrease of the normal parenchyma.
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and/or gadolinium chelates MR studies, both always
effective in dynamic phases.
In conclusion, our experience with normalized per-
centage quantitative evaluation of SI change after slow
bolus Resovist administration, allows us to propose
the following key points: (i) The main add-on value of
quantitative evaluation can be found in late phase-
acquisitions; the 10-min T2-weighted sequences per-
mit differentiation of malignant from benign hepatic
nodules, while the 10-min T1-weighted sequences
Figure 6. Graph-scatter plot T2. Classification of benign (1)
versus malignant (0) lesions on T2-weighted images. A cutoff
¼ 26% allowed 97.4% sensitivity and 97.7% specificity.
Figure 7. Graph-scatter plot T1. Differentiation of hemangi-
oma (1) from all other focal liver lesions (0) on T1-weighted
images. A cutoff ¼ þ40% permitted 90.5% sensitivity and
98.0% specificity.
Figure 5. a–f: Hepatocellular carcinoma. Unenhanced T1-weighted VIBE acquisition (a) shows a round well-defined hypoin-
tense lesion in the V-VIII segment of the liver. After slow bolus Resovist administration, on the hepatic artery phase (b) a
slight, heterogeneous enhancement can be detected, with subsequent washout phenomenon on the portal phase (c). At 10-
min T1-weighted acquisition a peripheral ring of enhancement is appreciable (d). On the unenhanced HASTE T2-weighted
sequence (e), the lesion appears heterogeneously hyper-iso-intense versus surrounding liver parenchyma without any signal
intensity change, also at quantitative analysis, on the 10-min contrast-enhanced acquisition (f), where the nodule appears
more hyperintense due to the signal loss of the remaining parenchyma.
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distinguish hemangiomas from all other focal liver
lesions. (ii) The enhancement obtained on dynamic
study seems to be more suitable and confident in he-
mangiomas and FNHs than in adenomas and HCCs,
even if only sometimes comparable with the enhance-
ment induced by liver-specific gadolinium chelates.
(iii) This quantitative approach could be useful in clas-
sification of a focal liver lesion which is not character-
ized by liver-specific gadolinium chelates CA.
REFERENCES
1. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the
liver and spleen: review of the first 5 years. AJR Am J Roentgenol
1990;155:943–950.
2. Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ. Diagnostic
efficacy and safety of MRI of the liver with superparamagnetic
iron oxide particles (SHU 555 A). J Magn Reson Imaging 2001;
14:595–601.
3. Shamsi K, Balzer T, Saini S, et al. Superparamagnetic iron oxide
particles (SHU 555 A): evaluation of efficacy in three doses for
hepatic MR imaging. Radiology 1998;206:365–371.
4. Halavaara JT, Lamminen AE, Bondestam S, Standertskjo¨ld-
Nordenstam CG, Hamberg LM. Detection of focal liver lesions
with superparamagnetic iron oxide: value of STIR and SE imag-
ing. J Comput Assist Tomogr 1994;18:897–904.
5. Ward J, Chen F, Guthrie JA, et al. Hepatic lesion detection after
superparamagnetic iron oxide enhancement: comparison of five
T2-weighted sequences at 1.0 T by using alternative-free response
receiver operating characteristic analysis. Radiology 2000;214:
159–166.
6. Kondo H, Kanematsu M, Hoshi H, et al. Preoperative detection of
malignant hepatic tumors: comparison of combined methods of
MR imaging with combined methods of CT. AJR Am J Roentgenol
2000;174:947–954.
7. Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B.
Detection of liver metastases: comparison of superparamagnetic
iron oxide-enhanced and unenhanced MR imaging at 1.5 T with
dynamic CT, intraoperative US, and percutaneous US. Radiology
1995;196:471–478.
8. Reimer P, Tombach B. Hepatic MRI with SPIO: detection and
characterization of focal liver lesions. Eur Radiol 1998;8:1198–
1204.
9. Grazioli L, Morana G, Kirchin MA, et al. MRI of focal nodular
hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and
SPIO (ferumoxides): an intra-individual comparison. J Magn
Reson Imaging 2003;17:593–602.
10. Kim YK, Kim CS, Kwak HS, Lee JM. Three-dimensional dynamic
liver MR imaging using sensitivity encoding for detection of hepa-
tocellular carcinomas: comparison with superparamagnetic iron
oxide-enhanced MR imaging. J Magn Reson Imaging 2004;20:
826–837.
11. Reimer P, Ja¨hnke N, Fiebich M, et al. Hepatic lesion detection
and characterization: value of nonenhanced MR imaging, super-
paramagnetic iron oxide-enhanced MR imaging, and spiral CT-
ROC analysis. Radiology 2000;217:152–158.
12. Chen F, Ward J, Robinson PJ. MR imaging of the liver and
spleen: a comparison of the effects on signal intensity of two
superparamagnetic iron oxide agents. Magn Reson Imaging 1999;
17:549–556.
13. Montet X, Lazeyras F, Howarth N, et al. Specificity of SPIO
particles for characterization of liver hemangiomas using MRI.
Abdom Imaging 2004;29:60–70.
14. Poeckler-Schoeniger C, Koepke J, Gueckel F, Sturm J, Georgi M.
MRI with superparamagnetic iron oxide: efficacy in the detection
and characterization of focal hepatic lesions. Magn Reson Imag-
ing 1999;17:383–392.
15. Namkung S, Zech CJ, Helmberger T, Reiser MF, Schoenberg SO.
Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with
ferucarbotran: efficacy for characterization of focal liver lesions.
J Magn Reson Imaging 2007;25:755–765.
16. Schnorr J, Wagner S, Abramjuk C, et al. Focal liver lesions:
SPIO, gadolinium, and ferucarbotran-enhanced dynamic T1
weighted and delayed T2-weighted MR imaging in rabbits. Radiol-
ogy 2006;240:90–100.
17. Wersebe A, Wiskirchen J, Decker U, et al. Comparison of Gado-
linium-BOPTA and Ferucarbotran-enhanced three-dimensional
T1-weighted dynamic liver magnetic resonance imaging in the
same patient. Invest Radiol 2006;41:264–271.
18. Grazioli L, Bondioni MP, Romanini L, et al. Superparamagnetic
iron oxide-enhanced liver MRI with SHU 555 A (RESOVIST): new
protocol infusion to improve arterial phase evaluation–a prospec-
tive study. J Magn Reson Imaging 2009;29:607–616.
19. Lee SW, Park SH, Kim KW, et al. Unenhanced CT for assessment
of macrovesicular hepatic steatosis in living liver donors: compar-
ison of visual grading with liver attenuation index. Radiology
2007;244:479–485.
20. Yamamoto H, Yamashita Y, Yoshimatsu S, et al. Hepatocellular
carcinoma in cirrhotic livers: detection with unenhanced and iron
oxide-enhanced MR imaging. Radiology 1995;195:106–112.
21. Van Beers BE, Lacrosse M, Jamart J, et al. Detection and
segmental location of malignant hepatic tumors: comparison of
ferumoxides-enhanced gradient-echo and T2-weighted spin-echo
MR imaging. AJR Am J Roentgenol 1997;168:713–717.
22. Tang Y, Yamashita Y, Arakawa A, et al. Detection of hepatocellu-
lar carcinoma arising in cirrhotic livers: comparison of gadolinium
and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol
1999;172:1547–1554.
23. Arbab AS, Ichikawa T, Araki T, et al. Detection of hepatocellular
carcinoma and its metastases with various pulse sequences
using superparamagnetic iron oxide (SHU-555-A). Abdom Imag-
ing 2000;25:151–158.
24. Kanematsu M, Itoh K, Matsuo M, et al. Malignant hepatic tumor
detection with ferumoxides-enhanced MR imaging with a 1.5-T
system: comparison of four imaging pulse sequences. J Magn
Reson Imaging 2001;13:249–257.
1020 Santoro et al.
